Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
about
Valproic acid induces autophagy by suppressing the Akt/mTOR pathway in human prostate cancer cells.Targeting the N-Terminal Domain of the Androgen Receptor: A New Approach for the Treatment of Advanced Prostate Cancer.Androgen Receptor Signaling in Bladder Cancer.Prognostic and predictive biomarkers in prostate cancer: latest evidence and clinical implications.Glycogen synthase kinase-3 inhibitors suppress the AR-V7-mediated transcription and selectively inhibit cell growth in AR-V7-positive prostate cancer cells.The Y-located proto-oncogene TSPY exacerbates and its X-homologue TSPX inhibits transactivation functions of androgen receptor and its constitutively active variants.The Androgen Receptor and VEGF: Mechanisms of Androgen-Regulated Angiogenesis in Prostate Cancer.LuCaP Prostate Cancer Patient-Derived Xenografts Reflect the Molecular Heterogeneity of Advanced Disease an--d Serve as Models for Evaluating Cancer Therapeutics.Dual effects of constitutively active androgen receptor and full-length androgen receptor for N-cadherin regulation in prostate cancer.Bipolar androgen therapy in men with metastatic castration-resistant prostate cancer after progression on enzalutamide: an open-label, phase 2, multicohort study.The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivation.Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting.BET inhibitors in metastatic prostate cancer: therapeutic implications and rational drug combinations.CTC-derived AR-V7 detection as a prognostic and predictive biomarker in advanced prostate cancer.Multimodal actions of the phytochemical sulforaphane suppress both AR and AR-V7 in 22Rv1 cells: Advocating a potent pharmaceutical combination against castration-resistant prostate cancer.DBC1 promotes castration-resistant prostate cancer by positively regulating DNA binding and stability of AR-V7.[Androgen receptor variants in prostate cancer].Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.Activation of UPR Signaling Pathway is Associated With the Malignant Progression and Poor Prognosis in Prostate Cancer.Non-invasive actionable biomarkers for metastatic prostate cancer.A Phase II Trial of Selinexor, an Oral Selective Inhibitor of Nuclear Export Compound, in Abiraterone- and/or Enzalutamide-Refractory Metastatic Castration-Resistant Prostate Cancer.Clinical, pharmacodynamic and pharmacokinetic results of a prospective phase II study on oral metronomic vinorelbine and dexamethasone in castration-resistant prostate cancer patients.Emerging biomarkers in the diagnosis of prostate cancer.Ipilimumab plus nivolumab and DNA-repair defects in AR-V7-expressing metastatic prostate cancer.
P2860
Q37204497-72D688A5-B865-4E24-94F4-646B464055ABQ37496652-5516D37A-59EF-4DDE-8AC1-B8BE0683CE02Q37676080-8AAB0256-9B46-41AF-A1A1-F8EE6C9DFF04Q38644658-22ED50A5-FEEE-4798-BAFB-1A22F42D212EQ38708121-0394F8C4-75A2-4075-BD0D-D5CB3CC4EB87Q38717520-F50D765B-8D5E-49B7-9B06-7B54F0133C0EQ39231548-BE70A516-C8A1-445C-9B76-16AF2B0577EAQ42315779-0970DE6F-FE82-4C96-93D2-753142EABB3CQ42700843-4DEB95A0-8022-40CA-A7A2-CBD789903CF3Q47191382-B2866509-14DB-4C7F-BFE9-2286F358AE40Q47273298-B727B083-3DCA-4D47-A857-E05C1045D7A5Q47281377-65D21A2F-62F2-4174-957B-6F6A2921DE43Q47651456-37CF78D8-29AD-4AEE-892A-A7155DFCDBDAQ47740995-80B68DB6-FC5A-45B1-970B-B9050C22293AQ47811299-BBEA603E-4B94-4795-AB77-7A84D5E2D526Q49712140-D873D33F-FB6F-490F-A292-48FADF70BC6BQ49845725-E6DFBC58-2FDD-402A-86A6-4B67A6C18E1BQ51068972-62B7349C-43A2-4917-8DE5-AF7B0508E4F0Q51414857-F10A4CD1-951F-4E74-8A68-A062D0984EBBQ51789456-A5BFC0E2-2F02-45E9-84D0-BD28556F97D3Q52682469-7295289F-8116-4CD2-8AD8-3F293FA0686AQ52852575-F1BE3EB3-F733-495A-A9FE-6180A1CE125EQ54964875-E9090B9D-7007-4C83-AE64-47A9DEA96421Q55504467-1774EF86-FAF0-456A-AD8A-B78FE1E7E09B
P2860
Androgen receptor variant-driven prostate cancer: clinical implications and therapeutic targeting.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Androgen receptor variant-driv ...... ons and therapeutic targeting.
@en
type
label
Androgen receptor variant-driv ...... ons and therapeutic targeting.
@en
prefLabel
Androgen receptor variant-driv ...... ons and therapeutic targeting.
@en
P2093
P2860
P356
P1476
Androgen receptor variant-driv ...... ons and therapeutic targeting.
@en
P2093
A J Armstrong
E S Antonarakis
P2860
P2888
P304
P356
10.1038/PCAN.2016.17
P577
2016-05-17T00:00:00Z